Amphotericin B activation of human genes encoding for cytokines

Journal of Infectious Diseases

Volumn 178, Issue 6, 1998, Pages 1726-1733

  Rogers, P David ^a   Jenkins, John K ^b   Chapman, Stanley W ^b   Ndebele, Kenneth ^b   Chapman, Brenda A ^b   Cleary, John D ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANIMAL CELL; ANTIFUNGAL ACTIVITY; ARTICLE; GENE ACTIVATION; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HYPOKALEMIA; MACROPHAGE; MONOCYTE; MOUSE; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

CELL LINE; CYCLOHEXIMIDE; CYTOKINES; DACTINOMYCIN; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; RECEPTORS, INTERLEUKIN-1; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031766789     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314495     Document Type: Article

References (27)

1. Cleary JD, Weisdorf D, Fletcher CV. Amphotericin B infusion related reactions: a randomized trial of differing infusion rates. DICP 1988;22:769-72.
2. Rogers PD, Chapman SW, Chapman BA, Cleary JD. Amphotericin B-induced transcriptional changes in human monocytic cell cytokine expression [abstract 98]. In: Program and abstracts of the 1997 Annual Meeting of the American College of Clinical Pharmacy (Phoenix). Kansas City, MO: American College of Clinical Pharmacy, 1997.
3. Cleary JD, Nolan RL, Chapman SW. Inhibition of interleukin 1 release from endotoxin or amphotericin B stimulated monocytes. Antimicrob Agents Chemother 1992;36:977-81.
4. Gelfand, JA, Kimball K, Burke JF, Dinarello CA. Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1 [abstract]. Clin Res 1988;36:465A.
5. Chia JKS, Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis 1989;159:113-6.
6. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever production by infusing amphotericin B. J Infect Dis 1987;156:784-9.
7. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
8. Rubartelli A, Bajetto A, Allavena G, Cozzolino F, Sitia R. Post-translational regulation of interleukin I secretion. Cytokine 1993;5:117-24.
9. Rubartelli A, Cozzolino F, Talio M, Sitia R. A novel secretory pathway for interleukin-1, a protein lacking a signal sequence. EMBO J 1990;9:1503-10.
10. Markham RB. Cell-mediated immunity. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992:62-76.
11. Butler B, Cerami A. Tumor necrosis factor, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988;57:505-18.
12. Brouckaert P, Fiers W. Tumor necrosis factor and the systemic inflammatory response syndrome. Curr Top Microbiol Immunol 1990;216:167-87.
13. Cleary JD, Chapman SW, Brown C. Cytokines as markers for amphotericin B adverse reactions [abstract 214]. In: Program and abstracts of the 1994 Annual Meeting of the American College of Clinical Pharmacy (St. Louis). Kansas City, MO: American College of Clinical Pharmacy, 1994.
14. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995;38:459-65.
15. Cleary JD, Chapman S. Cytokine expression by amphotericin B formulations [abstract 700]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993:45.
16. Endres S, Ghorbani R, Lonnemann G, Van Der Meer JWM, Dinarello CA. Measurement of immunoreactive interleukin-1β from human mononuclear cells: optimization of recovery, intrasubject, consistency, and comparison with interleukin-1α and tumor necrosis factor. Clin Immunol Immunopathol 1988;49:424-38.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
18. Arend WP, Gordon DF, Wood WM, Janson RW, Joslin FG, Jameel S. IL-1 production in human monocytes is regulated at multiple levels. J Immunol 1986;143:118-26.
19. Baldari C, Merray JAM, Ghiara P, Cesareni G, Galeotti CL. A novel leader peptide which allows efficient secretion of a fragment of human IL-1β in Saccharomyces cerevisiae. EMBO J 1987;6:229-34.
20. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
21. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993;44:643-53.
22. Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 1992;14(suppl):S114-9.
23. Lin HS, Medoff G, Kobayashi GS. Effects of amphotericin B on macrophages and their precursor cells. Antimicrob Agents Chemother 1977;11:154-8.
24. Chapman HA, Hibbs JB. Modulation of macrophage tumoricidal capability by polyene antibiotics: support for membrane lipid as a regulatory determinant of macrophage function. Proc Natl Acad Sci USA 1978;75:4349-53.
25. Mozaffarian N, Berman JW, Casadevall A. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother 1997;41:1825-9.
26. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
27. Alberts B, Bray D, Lewis J, et al., eds. Molecular biology of the cell. 3rd ed. New York: Garland Publishing, 1995:240.